Olympus Corporation
http://www.olympus.co.jp
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Olympus Corporation
Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
Tech Transfer Roundup: Santhera Exits Congenital Muscular Dystrophy Pact To Focus On DMD
Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.
Asia Deal Watch: SV Investment And Orange Grove Will Team Up On New Company Effort
Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.
Tumbling Medtech Investment Records Leave A Hill To Climb In 2022
Listing all-time high medtech IPO and M&A activity, Silicon Valley Bank’s 2021 health care investments and exits report made good reading after the market uncertainties induced by the pandemic a year earlier. But where does the sector go now after such a sterling year?
Company Information
- Industry
- Medical Devices
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
-
Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- ARC Medical Design Ltd
- Gyrus Group PLC
- Image stream Medical, Inc.
- Olympus Biotech
- Olympus Optical Co., Ltd.
- Olympus Surgical America
- Spiration Inc.
- Quest Innovations B.V.
- Veran Medical Technologies, Inc.